FURI | Fall 2022
Analysis of Volatile Organic Compounds Specific to the Treatment of Small Cell Lung Cancer by Cisplatin and Etoposide
Lung cancer is the leading cause of cancer-related deaths globally, claiming 1.59 million lives annually. Numerous efforts have been made to reduce mortality, however, 33% of small cell lung cancer patients still experience a relapse within the first two years. This challenge is driven by limitations in diagnostics, which are unable to accurately evaluate the tumor treatment response over time. Due to altered biochemical pathways, I hypothesize that H345 cancer cells will have unique Volatile Organic Compounds (VOCs) expression under the administration of chemotherapeutics. The successful identification of treatment-responsive VOCs will enable the noninvasive evaluation of lung cancer treatments.
Youssef H. Abdellatif
Hometown: Cairo, Egypt
Graduation date: Spring 2023